Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

HistoSonics, the developer of the Edison histotripsy system and histotripsy therapy platform, announced a management-led majority ...

Royal Philips recently announced FDA 510(k) clearance of the latest version of the company’s UroNav system for image-guided ...

The Society of Interventional Oncology (SIO) recently announced the completion of enrollment for its clinical trial, ...

Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, announced ...

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.